NIHS

National Institutes of Health Launches its ACTIV-5 “Big Effect Trial” Evaluating Humanigen’s Lenzilumab™ as Potential COVID-19 Therapy

Retrieved on: 
Tuesday, October 13, 2020
Research, Infectious diseases, Clinical trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Branches of biology, Cytokines, Medical specialties, Cell biology, Granulocyte-macrophage colony-stimulating factor, Lenzilumab, Coronavirus disease, Vaccine, NIHS, National Institutes of Health, Activ, Macrophage colony-stimulating factor, ACTIV, ACTIV-5/BET, Humanigen, Inc.

Humanigen is providing lenzilumab for the study, which is fully funded by NIH.

Key Points: 
  • Humanigen is providing lenzilumab for the study, which is fully funded by NIH.
  • ACTIV-5/BET is being conducted in collaboration with the NIHs public-private partnership Accelerating COVID-19 Therapeutic Innovations and Vaccines ( ACTIV ) program.
  • We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.
  • You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release.

Preclinical Study Shows SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Produces Neutralizing Antibodies

Retrieved on: 
Wednesday, July 22, 2020
Health, Infectious diseases, Research, Pharmaceutical, Science, Biotechnology, Virology, Medical specialties, Laboratory techniques, Zoonoses, Natural sciences, Chemistry, Plaque reduction neutralization test, Peplomer, Coronavirus disease, NIHS, CoV, Assay

Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company) announces that the National Institutes of Health (the NIH) created stabilized pre-fusion spike protein (CoV-2 S-2P) licensed by the Company has generated neutralizing antibodies in mice during immunization against SARS-CoV-2, the virus that causes COVID-19.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company) announces that the National Institutes of Health (the NIH) created stabilized pre-fusion spike protein (CoV-2 S-2P) licensed by the Company has generated neutralizing antibodies in mice during immunization against SARS-CoV-2, the virus that causes COVID-19.
  • The NIHs preclinical study shows that this spike protein, adjuvanted with the TLR-4-agonist Sigma Adjuvant System (a TLR-4 agonists that induces T cell activation), generates neutralizing antibody titers in both a pseudovirus neutralization assay and a plaque reduction neutralization titer (PRNT) assay.
  • In March 2020 Noachis Terra Inc., a wholly owned subsidiary of Oragenics, acquired a non-exclusive license from the NIH for this stabilized prefusion CoV-2 spike protein.
  • Oragenics assumes no responsibility to update any forward-looking statements contained in this press release or with respect to the matters described herein.

7 Hills Pharma to Deliver Video Presentation At BIO Digital 2020 June 8 – 12

Retrieved on: 
Thursday, June 4, 2020
Articles, NIHS, Small Business Innovation Research, Biotechnology, National Institutes of Health, Business, Health

His participation is part of a partnership between the Biotechnology Innovation Organization (BIO) and the U.S. National Institutes of Health (NIH) aimed at highlighting select emerging biomedical companies within an Innovation Zone of the BIO Digital online platform.

Key Points: 
  • His participation is part of a partnership between the Biotechnology Innovation Organization (BIO) and the U.S. National Institutes of Health (NIH) aimed at highlighting select emerging biomedical companies within an Innovation Zone of the BIO Digital online platform.
  • The 7 Hills Pharma video can be viewed in the Available on Demand company presentation site of the digital convention.
  • We want to thank BIO and the NIHs Small Business Innovation Research (SBIR) grant program for making it possible for 7 Hills Pharma to participate in this convention, Dr. Marathi said.
  • 7 Hills Pharma has developed a novel, systemic means of safely improving the immune system response of any immunotherapy.

Alerus Financial Corporation Reports First Quarter 2020 Net Income of $5.4 Million

Retrieved on: 
Tuesday, April 28, 2020
Finance, Banking, Professional services, Insurance, Human resources, Nursing research, NIHS, National Institutes of Health, Health, Articles, Organizations

Earlier this month, the Future of Privacy Forum (FPF) submitted comments to the National Institutes of Health (NIH) on the NIH-Wide Strategic Plan covering fiscal years 2021-2025. In the letter, Health Policy Counsel Rachele Hendricks-Sturrup and Artificial Intelligence Policy Counsel Sara Jordan propose the addition of a cross-cutting theme to NIH’s strategic plan as well […]

Key Points: 

Earlier this month, the Future of Privacy Forum (FPF) submitted comments to the National Institutes of Health (NIH) on the NIH-Wide Strategic Plan covering fiscal years 2021-2025. In the letter, Health Policy Counsel Rachele Hendricks-Sturrup and Artificial Intelligence Policy Counsel Sara Jordan propose the addition of a cross-cutting theme to NIH’s strategic plan as well […]

FPF Submits Comments to NIH on the NIH-Wide Strategic Plan for Fiscal Years 2021-2025

Retrieved on: 
Tuesday, April 28, 2020
Nursing research, NIHS, Health, Articles, National Institutes of Health, Organizations

Earlier this month, the Future of Privacy Forum (FPF) submitted comments to the National Institutes of Health (NIH) on the NIH-Wide Strategic Plan covering fiscal years 2021-2025.

Key Points: 
  • Earlier this month, the Future of Privacy Forum (FPF) submitted comments to the National Institutes of Health (NIH) on the NIH-Wide Strategic Plan covering fiscal years 2021-2025.
  • In the letter, Health Policy Counsel Rachele Hendricks-Sturrup and Artificial Intelligence Policy Counsel Sara Jordan propose the addition of a cross-cutting theme to NIHs strategic plan as well as opportunities for collaboration between the two organizations.
  • Consider balancing health data privacy with data access and use as an additional cross-cutting theme.
  • Support research resources and infrastructure with ethical review models.

Dr. Vivian W. Pinn, Founding Director, Office of Research on Women’s Health at the NIH, Addresses Graduates of Ross University School of Medicine

Retrieved on: 
Saturday, May 18, 2019
Women, Education, University, Continuing, Health, Consumer, African-American, General Health, Adtalem Global Education, Ross University School of Medicine, NIHS, Vivian Pinn

addressing Ross University School of Medicine graduating class at commencement (Photo: Business Wire)

Key Points: 
  • addressing Ross University School of Medicine graduating class at commencement (Photo: Business Wire)
    Vivian W. Pinn, M.D., was the keynote speaker.
  • She was the inaugural full-time director of the Office of Research on Womens Health at the National Institutes of Health (NIH) beginning in 1991 and associate director of NIH for Womens Health Research from 1994 until her retirement in 2011.
  • Dr. Pinn led the implementation of NIHs research inclusion policies and developed the national strategic plan for womens health research.
  • Ross University School of Medicine (RUSM) is an institution of Adtalem Global Education (NYSE: ATGE), a global education provider headquartered in the United States.